1. Introduction
Coronaviruses are among the causes of upper respiratory tract infections first observed in China [1]. Currently, due to multiple biological problems caused by it [3], effective preventions are required; however, there remains no reliable treatment or vaccine to treat HCoV infection. It is essential to develop a vaccine or medication to spread the disease caused by the virus. Immunogenetic/bioinformatics-based approaches to vaccine development are determined and used to create new vaccines. Despite repeated severe epidemics and inappropriate medication, little progress has been made on the epitope-based vaccine for HCoV. Therefore, using rapid advances in the sequencing of pathogen genomes and protein sequencing databases and the prompt and flexible approach of insilico methods have become prevalent in the design of vaccines, which led us to design this research. 
2. Materials & methods
In this study, the sequence of protein spike coronavirus were selected from NCBI, protein sequence retrieval was determined. Besides, specific T and B cell epitopes required for producing the Chimber vaccine were obtained using servers such as IEDB. The selected epitopes’ antigenicity, allergenicity, and toxicity were further investigated by other servers, such as VaxiJenv2.0, AllerTOP, and Toxinpred [8, 9]. The initial chimer composition of the epitope vaccine was then configured with the help of unique linkers. Then, to evaluate the structure of the Bimer vaccine concerning structure and connectivity to B cells and MHCI, II compounds; to study the two-dimensional structure and position of amino acids and bonds in the model of the immunogenic system; also exploring the physicochemical and stability of the model vaccine by other software bioinformatics servers, like PRABI, protParam was paid. Finally, for binding against HLA molecules, silico docking techniques were examined to evaluate the interaction with the epitope through the Cluspro server.
3. Results
The obtained results indicated that the safety structure created in terms of the incilico evaluations of two-dimensional structures and especially in terms of having a sufficient percentage of the alpha helix was in good condition. Furthermore, its three-dimensional structure has a similarity of 83.33 with the composition of structures structured in the SWISSMODEL server (Figure 1).

Moreover, in checking the percentage of the optimal placement of amino acids and bonds by PROCHECK server with (99.6), the rate of optimal placement of amino acids in the chimer structure was created. Besides, the created chimeric structure was non-toxic and allergenic and had a good antigenicity, i.e., confirmed by bioinformatics software. The immunogenic chimeric structure was formed as a stable compound (instability index 33.93) and had a favorable half-life and suitable physicochemical conditions respecting solubility.
4. Discussion and conclusion
Developing new and timely vaccines to protect against the increasing global disease burden is very important [30]. Therefore, integrated computational approaches can predict candidates for immunogenic structures (vaccines) against pathogens, including HCoV, using valid methods previously described. The immunogenic structure prepared in this research process after confirming the physicochemical conditions and two-dimensional and three-dimensional structures and immunogenicity and angiogenesis [22, 23] in the docking process could favorably interact with some components of the selected immune system (HLA) with high frequency (HLA-A0201 and HLA-DRB1-0101) in populations. Accordingly, it indicates the optimal identification of this immunogenic structure by the two main parts of the immune system called humoral immunity and cellular immunity and stimulation to produce immunogenicity in the host body. This promises good immunity in the host body. However, further proof of these results requires clinical phase processes [27, 28, 29].

Ethical Considerations
Compliance with ethical guidelines
All ethical principles are considered in this article. Participants were informed about the research objective and its implementation stages. They also made sure their information was confidential. The principles of the Helsinki Convention were also observed.

Funding
This research did not receive any financial assistance from financial organizations in the public, commercial or non-profit sectors and is a personal project.

Authors' contributions
All authors met the standard writing standards based on the recommendations of the International Committee of Medical Journal Publishers.

Conflicts of interest
The authors stated no conflicts of interest.

Acknowledgements
We would like to thank appreciation and thanks the professors of the Faculty of Veterinary Medicine of Shahid Chamran University of Ahvaz who had the necessary cooperation to prepare this research work. 
 
 

1. González JM, Gomez-Puertas P, Cavanagh D, Gorbalenya AE, Enjuanes L. A comparative sequence analysis to revise the current taxonomy of the family Coronaviridae. Arch Virol. 2003; 148(11):2207-35. [DOI:10.1007/s00705-003-0162-1] [PMID] [PMCID]
2. Cavanagh D, Mawditt K, Welchman Dde B, Britton P, Gough RE. Coronaviruses from pheasants (Phasianus colchicus) are genetically closely related to coronaviruses of domestic fowl (infectious bronchitis virus) and turkeys. Avian Pathol. 2002; 31(1):81-93. [DOI:10.1080/03079450120106651] [PMID]
3. Yoo D, Deregt D. A single amino acid change within antigenic domain II of the spike protein of bovine Coronavirus confers resistance to virus neutralization. Clin Diagn Lab Immunol. 2001; 8(2):297-302. [DOI:10.1128/CDLI.8.2.297-302.2001] [PMID] [PMCID]
4. Bourdette DN, Edmonds E, Smith C, Bowen JD, Guttmann CR, Nagy ZP, et al. A highly immunogenic trivalent T cell receptor peptide vaccine for multiple sclerosis. Mult Scler. 2005; 11(5):552-61. [DOI:10.1191/1352458505ms1225oa] [PMID]
5. López JA, Weilenman C, Audran R, Roggero MA, Bonelo A, Tiercy JM, et al. A synthetic malaria vaccine elicits a potent CD8(+) and CD4(+) T lymphocyte immune response in humans. Implications for vaccination strategies. Eur J Immunol. 2001; 31(7):1989-98. [DOI:10.1002/1521-4141(200107)31:73.0.CO;2-M]
6. Knutson KL, Schiffman K, Disis ML. Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest. 2001; 107(4):477-84. [DOI:10.1172/JCI11752] [PMID] [PMCID]
7. Petrovsky N, Brusic V. Computational immunology: The coming of age. Immunol Cell Biol. 2002; 80(3):248-54. [DOI:10.1046/j.1440-1711.2002.01093.x] [PMID]
8. Doytchinova IA, Flower DR. VaxiJen: A server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics. 2007; 8:4. [DOI:10.1186/1471-2105-8-4] [PMID] [PMCID]
9. Liao L, Noble WS. Combining pairwise sequence similarity and support vector machines for detecting remote protein evolutionary and structural relationships. J Comput Biol. 2003; 10(6):857-68. [DOI:10.1089/106652703322756113] [PMID]
10. Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990; 276(1-2):172-4. [DOI:10.1016/0014-5793(90)80535-Q]
11. Emini EA, Hughes JV, Perlow DS, Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol. 1985; 55(3):836-9. [DOI:10.1128/jvi.55.3.836-839.1985] [PMID] [PMCID]
12. Karplus PA, Schulz GE. Prediction of chain flexibility in proteins. Naturwissenschaften. 1985; 72(4):212-3. [DOI:10.1007/BF01195768]
13. Larsen JE, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006; 2:2. [DOI:10.1186/1745-7580-2-2] [PMID] [PMCID]
14. Chou PY, Fasman GD. Empirical predictions of protein conformation. Annu Rev Biochem. 1978; 47:251-76. [DOI:10.1146/annurev.bi.47.070178.001343] [PMID]
15. Dimitrov I, Bangov I, Flower DR, Doytchinova I. AllerTOP v. 2—a server for in silico prediction of allergens. Journal of Molecular Modeling. 2014; 20(6):1-6. [DOI:10.1007/s00894-014-2278-5]
16. Dimitrov I, Naneva L, Doytchinova I, Bangov I. AllergenFP: Allergenicity prediction by descriptor fingerprints. Bioinformatics. 2014; 30(6):846-51. [DOI:10.1093/bioinformatics/btt619]
17. Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Open Source Drug Discovery Consortium, Raghava GP. In silico approach for predicting toxicity of peptides and proteins. PloS One. 2013; 8(9):e73957. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0073957
18. Thévenet P, Shen Y, Maupetit J, Guyon F, Derreumaux P, Tuffery P. PEP-FOLD: An updated de novo structure prediction server for both linear and disulfide bonded cyclic peptides. Nucleic Acids Res. 2012; 40(W1):W288-93. [DOI:10.1093/nar/gks419] [PMID] [PMCID]
19. Shen Y, Maupetit J, Derreumaux P, Tufféry P. Improved PEP-FOLD approach for peptide and miniprotein structure prediction. J Chem Theory Comput. 2014; 10(10):4745-58. [DOI:10.1021/ct500592m] [PMID]
20. Zhang Y, Skolnick J. Scoring function for automated assessment of protein structure template quality. Proteins. 2004; 57(4):702-10. [DOI:10.1002/prot.20264]
21. Ali M, Pandey RK, Khatoon N, Narula A, Mishra A, Prajapati VK. Exploring dengue genome to construct a multi-epitope based subunit vaccine by utilizing immunoinformatics approach to battle against dengue infection. Sci Rep. 2017; 7(1):9232. [DOI:10.1038/s41598-017-09199-w] [PMID] [PMCID]
22. Ikai A. Thermostability and aliphatic index of globular proteins. J Biochem. 1980; 88(6):1895-8. [PMID]
23. Rose GD, Gierasch L, Smith JA. Turns in peptides and proteins. Adv Protein Chem. 1985; 37:1-109. [DOI:10.1016/S0065-3233(08)60063-7]
24. Larsen MV, Lundegaard C, Lamberth K, Buus S, Lund O, Nielsen M. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics. 2007; 8:424. [DOI:10.1186/1471-2105-8-424] [PMID] [PMCID]
25. Zhang M, Ishii K, Hisaeda H, Murata S, Chiba T, Tanaka K, et al. Ubiquitin-fusion degradation pathway plays an indispensable role in naked DNA vaccination with a chimeric gene encoding a syngeneic cytotoxic T lymphocyte epitope of melanocyte and green fluorescent protein. Immunology. 2004; 112(4):567-74. [DOI:10.1111/j.1365-2567.2004.01916.x] [PMID] [PMCID]
26. Yang X, Yu X. An introduction to epitope prediction methods and software. Rev Med Virol. 2009; 19(2):77-96. [DOI:10.1002/rmv.602] [PMID]
27. Singh H, Raghava G. ProPred: Prediction of HLA-DR binding sites. Bioinformatics. 2001; 17(12):1236-7. [DOI:10.1093/bioinformatics/17.12.1236] [PMID]
28. Lapelosa M, Gallicchio E, Arnold GF, Arnold E, Levy RM. In silico vaccine design based on molecular simulations of rhinovirus chimeras presenting HIV-1 gp41 epitopes. J Mol Biol. 2009; 385(2):675-91. [DOI:10.1016/j.jmb.2008.10.089] [PMID] [PMCID]
29. Chakraborty S, Chakravorty R, Ahmed M, Rahman A, Waise TM, Hassan F, et al. A computational approach for identification of epitopes in dengue virus envelope protein: A step towards designing a universal dengue vaccine targeting endemic regions. In Silico Biol. 2010; 10(5-6):235-46. [DOI:10.3233/ISB-2010-0435] [PMID]
30. Islam R, Sakib MS, Zaman A. A computational assay to design an epitope-based peptide vaccine against chikungunya virus. Future Virol. 2012; 7(10):1029-42. [DOI:10.2217/fvl.12.95]
31. Hasan MA, Hossain M, Alam MJ. A computational assay to design an epitope-based Peptide vaccine against Saint Louis encephalitis virus. Bioinform Biol Insights. 2013; 7:347-55. [DOI:10.4137/BBI.S13402] [PMID] [PMCID]
32. Twiddy SS, Holmes EC, Rambaut A. Inferring the rate and time-scale of dengue virus evolution. Mol Biol Evol. 2003; 20(1):122-9. [DOI:10.1093/molbev/msg010] [PMID]
33. Manzin A, Solforosi L, Petrelli E, Macarri G, Tosone G, Piazza M, et al. Evolution of hypervariable region 1 of hepatitis C virus in primary infection. J Virol. 1998; 72(7):6271-6. [DOI:10.1128/JVI.72.7.6271-6276.1998] [PMID] [PMCID]
34. Christie JM, Chapel H, Chapman RW, Rosenberg WM. Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus. Hepatology. 1999; 30(4):1037-44. [DOI:10.1002/hep.510300403] [PMID]
35. Ma C, Li Y, Wang L, Zhao G, Tao X, Tseng CT, et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. Vaccine. 2014; 32(18):2100-8. [DOI:10.1016/j.vaccine.2014.02.004] [PMID] [PMCID]
36. Yang ZY, Kong WP, Huang Y, Roberts A, Murphy BR, Subbarao K, et al. A DNA vaccine induces SARS Coronavirus neutralization and protective immunity in mice. Nature. 2004; 428(6982):561-4. [DOI:10.1038/nature02463] [PMID] [PMCID]
37. Sudhakar A, Robin G, Boyd L, Agnihothram S, Gopal R, Yount BL, et al. Platform strategies for rapid response against emerging coronaviruses: MERS-CoV serologic and antigenic relationships in vaccine design. The Journal of Infectious Diseases. 2013; 10:1093.
38. McKeever TM, Lewis SA, Smith C, Hubbard R. Vaccination and allergic disease: A birth cohort study. Am J Public Health. 2004; 94(6):985-9. [DOI:10.2105/AJPH.94.6.985] [PMID] [PMCID]
39. Zhou Y, Yang Y, Huang J, Jiang S, Du L. Advances in MERS-CoV vaccines and therapeutics based on the receptor-binding domain. Viruses. 2019; 11(1):60. [DOI:10.3390/v11010060] [PMID] [PMCID]
40. Li Y-H, Gao H, Xiao Y, Weng T, Yu D, Hu C, et al. Bioinformatics analysis on potential anti-viral targets against spike protein of MERS-CoV. 9th international conference on information technology in medicine and education (ITME), 2018 Oct 19-21,  Hangzhou, China. [DOI:10.1109/ITME.2018.00026]
41. Mubarak A, Alturaiki W, Hemida MG. Middle east respiratory syndrome coronavirus (MERS-CoV): Infection, immunological response, and vaccine development. J Immunol Res. 2019; 2019:6491738. [DOI:10.1155/2019/6491738.. https://www.hindawi.com/journals/jir/2019/6491738/] [PMID] [PMCID]
42. Shi J, Zhang J, Li S, Sun J, Teng Y, Wu M, et al. Epitope-based vaccine target screening against highly pathogenic MERS-CoV: An in silico approach applied to emerging infectious diseases. PLoS ONE. 2015; 10:e0144475. [DOI:10.1371/journal.pone.0144475] [PMID] [PMCID]